14-day medication follow-up regimen for Mavaceta/Mefanto

Mavacamten (mavacamten) is the first innovative drug to improve the symptoms of patients with obstructive hypertrophic cardiomyopathy (HCM) through the inhibition of cardiac myosin. Its medication management emphasizes gradual progress and strict monitoring. The 14-day medication follow-up plan is a critical stage in the treatment process of Mavakatai, which is related to whether the drug can safely reach steady-state blood concentration and optimal efficacy.

Generally, the starting dose of Mavacartide is 5 mg once daily, which can be individually adjusted based on the patient's left ventricular ejection fraction (LVEF), left ventricular outflow tract pressure gradient (LVOT), and clinical tolerance. After 14 days of treatment, the doctor will conduct an initial efficacy evaluation based on the improvement of the patient's cardiac function. The main goal of this phase is to ensure that myocardial contractile function declines within a controllable range to avoid the risk of heart failure, while also observing whether drug metabolism is affected by individual genotype or other drugs.

In treatment guidelines,an echocardiogram is usually recommended at 14 days to assess whether LVEF remains ≥55% and to monitor the coordination of diastole and contraction. If the patient tolerates it well and has no obvious side effects, the drug can be continued to be used at the original dose for 8 weeks before the next round of dose adjustment and follow-up. If slight dizziness, fatigue or bradycardia occurs, the adjustment time can be appropriately delayed or the dose increase can be suspended under the guidance of a doctor.

For patients who are taking CYP2C19 or CYP3A4 inhibitors in combination, special attention should be paid to the risk of cumulative drug concentration after 14 days. Some patients may experience an increase in blood drug concentration when metabolizing slowly, and should follow the doctor's guidance to lower the dose by one level, such as from 10 mg to 5 mg or from 5 mg to 2.5 mg. If LVEF is detected to be lower than 50% during this period, treatment should be interrupted immediately and restarted after cardiac function has recovered.

It is worth noting that the efficacy of Mavaceta is not fully visible in a short period of time. Most patients gradually experience improvement in dyspnea and enhanced exercise tolerance after taking the drug for several weeks, while significant changes in cardiac remodeling usually require continuous use for several months to appear stably.

Reference materials:https://bnf.nice.org.uk/drugs/mavacamten/